RayzeBio (RayzeBio) Interest Expense : $0.00 Mil (TTM As of Sep. 2023)

View and export this data going back to 2023. Start your Free Trial

What is RayzeBio Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. RayzeBio's interest expense for the three months ended in Sep. 2023 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. RayzeBio's Operating Income for the three months ended in Sep. 2023 was $ -21.65 Mil. RayzeBio's Interest Expense for the three months ended in Sep. 2023 was $ 0.00 Mil. GuruFocus does not calculate RayzeBio's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

RayzeBio Interest Expense Historical Data

The historical data trend for RayzeBio's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RayzeBio Interest Expense Chart

RayzeBio Annual Data

Trend

Dec20

Dec21

Dec22

Interest Expense

RayzeBio Quarterly Data
	Dec20	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23
Interest Expense	Get a 7-Day Free Trial			-	-	-	-	-

RayzeBio Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

RayzeBio (NAS:RYZB) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

RayzeBio's Interest Expense for the three months ended in Sep. 2023 was $0.00 Mil. Its Operating Income for the three months ended in Sep. 2023 was $-21.65 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2023 was $8.46 Mil.

RayzeBio's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as

GuruFocus does not calculate RayzeBio's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. RayzeBio inc has enough cash to cover all of its debt. Its financial situation is stable.

RayzeBio (RayzeBio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RayzeBio inc (NAS:RYZB) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

5505 Morehouse Drive, Suite 300, San Diego, CA, USA, 92121

Website

https://www.rayzebio.com

RayzeBio inc is a company operating as vertically integrated radiopharmaceutical therapeutics company. The main objective of the company is defeating cancer with radiopharmaceutical medicines. It has a created a pipeline of multiple drug candidates, in therapeutic areas with significant market opportunities. They have a portfolio of potential RPT drug and development candidates that includes late-stage clinical programs, development programs and discovery programs.

Executives

Hauwermeiren Timothy Van	director	C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Maha Katabi	director	SOFINNOVA INVESTMENTS, 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Viking Global Opportunities Drawdown Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Drawdown Portfolio Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Arvind Kush	officer: Chief Financial Officer	C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Wellington Biomedical Innovation Master Investors (cayman) Ii L.p.	10 percent owner	280 CONGRESS STREET, BOSTON MA 02210
Versant Ventures Vii Gp-gp, Llc	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Ventures Vii Gp, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Kenneth Song	director, officer: President and Chief Executive	C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Susan Moran	officer: Chief Medical Officer	1232 RICHARDSON AVE, LOS ALTOS CA 94024
Venbio Global Strategic Gp Iii, L.p.	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Venbio Global Strategic Gp Iii, Ltd	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCI CA 94158
Venbio Global Strategic Fund Iii, L.p.	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Redmile Biopharma Investments Ii, L.p.	10 percent owner	LETTERMAN DIGITAL ARTS CENTER, ONE LETTERMAN DRIVE, SUITE D3-300, SAN FRANCISCO CA 94129